SCGB1D5P

Across TCGA pan-cancer cohorts, SCGB1D5P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated SCGB1D5P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SCGB1D5P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SCGB1D5P expression acts as an unfavorable survival marker, although some lineages such as PAAD and GBM show a favorable association.

LIHC, PAAD, and KIRC are the cancer types where SCGB1D5P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.320	0.780	<.001	99	view →
PAAD	DFS	Tertile	All	0.820	0.240	<.001	72	view →
KIRC	OS	Tertile	All	0.443	0.640	.011	48	view →
GBM	DFS	Tertile	All	0.636	0.218	.021	27	view →
MESO	OS	Tertile	All	0.659	0.232	.007	21	view →
TGCT	DFS	Tertile	All	0.407	0.805	.029	18	view →
BLCA	OS	Tertile	All	0.188	0.609	.020	18	view →
THCA	DFS	Tertile	All	0.573	0.868	.015	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SCGB1D5P–LIHC (OS)

Open the LIHC breakdown →